Who are Xylometazoline - intranasal application's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Norepinephrine intravenous infusion, Doxazosin (drug), Arotinolol Hydrochloride, Inhaled Epoprostenol and phenylephrine, Cyclopentolate+tropicamide+phenylephrine, Beta Blockers Carvedilol Phosphate.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/xylometazoline-intranasal-application.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Xylometazoline - intranasal application — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Xylometazoline - intranasal application (Xylometazoline - intranasal application) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alpha-1 adrenergic agonist (nasal decongestant). Area: Otolaryngology / Respiratory.

marketed Alpha-1 adrenergic agonist (nasal decongestant) Alpha-1 adrenergic receptor Otolaryngology / Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

Xylometazoline - intranasal application (Xylometazoline - intranasal application) — Association Asthma, Bulgaria. Xylometazoline is a selective alpha-1 adrenergic receptor agonist that constricts blood vessels in the nasal mucosa, reducing congestion and swelling.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Xylometazoline - intranasal application TARGET	Xylometazoline - intranasal application	Association Asthma, Bulgaria	marketed	Alpha-1 adrenergic agonist (nasal decongestant)	Alpha-1 adrenergic receptor
Norepinephrine intravenous infusion	Norepinephrine intravenous infusion	University of Sao Paulo	marketed	Catecholamine; sympathomimetic amine	Alpha-1 adrenergic receptor; beta-1 adrenergic receptor
Doxazosin (drug)	Doxazosin (drug)	Japan Heart Foundation	marketed	Alpha-1 adrenergic receptor antagonist	Alpha-1 adrenergic receptor
Arotinolol Hydrochloride	Arotinolol Hydrochloride	Sumitomo Pharma (Suzhou) Co., Ltd.	marketed	Alpha-beta blocker	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor
Inhaled Epoprostenol and phenylephrine	Inhaled Epoprostenol and phenylephrine	University Health Network, Toronto	marketed	Prostacyclin analog with alpha-1 adrenergic agonist	Prostacyclin receptor (IP receptor); alpha-1 adrenergic receptor
Cyclopentolate+tropicamide+phenylephrine	Cyclopentolate+tropicamide+phenylephrine	Pontificia Universidad Catolica de Chile	marketed	Anticholinergic + sympathomimetic combination	Muscarinic acetylcholine receptors (M1-M5); alpha-1 adrenergic receptor
Beta Blockers Carvedilol Phosphate	Beta Blockers Carvedilol Phosphate	Seoul National University Hospital	marketed	Beta blocker (non-selective, with alpha-1 blocking activity)	Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Alpha-1 adrenergic receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Alpha-1 adrenergic agonist (nasal decongestant) class)

Association Asthma, Bulgaria · 1 drug in this class
Brian J Lipworth · 1 drug in this class
Rigshospitalet, Denmark · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Xylometazoline - intranasal application — Competitive Intelligence Brief. https://druglandscape.com/ci/xylometazoline-intranasal-application. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab